BB's Stock Haven

[gckitty]

IGNT NEWS~


Ingen Receives $100,000 Purchase Order From Oxygen Supplier for New Oxyview-Nasal Cannula

* Press Release
* Source: Ingen Technologies, Inc.
* On Friday July 17, 2009, 4:15 pm EDT


YUCAIPA, Calif., July 17, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 Oxyview-Nasal Cannulas.

"This is a positive indication that the new Oxyview Nasal Cannula is attractive to oxygen suppliers on a global basis," stated Thomas J. Neavitt, Chief Financial officer for Ingen Technologies.

The Oxyview flow meter is a significant advance in the technology. When first launched in November 2007, it represented a new generation of pneumatic real-time safety devices. It has some notable features: accurate to within plus-minus 3% and versatile enough to work with all respiratory equipment -- CPAP, concentrators, liquid and gas cylinders, on-demand conservers and more. It is not gravity-dependent and so can be placed at any point in the tubing, even by the patients themselves. Having the device close by for easy viewing allows the patient assurance and confidence, knowing that there is a flow of oxygen at the correct level. They are also able to quickly see if the regulator or concentrator is not working properly.

Further benefits are that Ingen Technologies manufactures the reusable Oxyview device that retails for $24.95 and comes with a life-time warranty. The company also manufactures the new disposable Oxyview Nasal Cannula for adults, children and infants. This novel device sells for only $5.75 and is a quality soft-tip cannula. The infant device measures either from 0-6 liters/minute or from 0-3 liters/minute in increments of one-quarter.

The significance of this new device is that it encompasses the flow device within a cannula -- the flow meter cannot be removed and the entire assembly is ultimately disposable. Yet the cost is comparable to the cost of a conventional cannula, but with all the benefits of Oxyview. Although budget constraints are hitting everybody hard, the Oxyview Nasal Cannula should greatly decrease unnecessary service calls. So the investment made in the cost of the devices can be recovered by not incurring the expense of those unnecessary calls. It is a straightforward financial justification!

Regulatory requirements are also a factor. Gary Scalf, V/P Respiratory Operations for Specialized Medical Services, Milwaukee, WI has commented that some state inspectors are starting to require a quick and simple visual detection of oxygen flow. In his opinion, the Oxyview meets these requirements.

And most important of all is the response from patients. They are very pleased with the Oxyview and not surprisingly, report that it meets their need to be reassured that oxygen is being supplied when and where it matters most. That is the ultimate benefit.

We all need oxygen in the right place at the right time and at the right concentration. For those requiring supplemental oxygen, these criteria are even more critical. The Oxyview not only allows the patient to be reassured about delivery and flow of oxygen, but also does so with considerable economic benefits to the supplier. Everyone benefits from this simple, elegant and effective device!

About Oxyview:

Oxyview is a proprietary medical device with U.S. issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where, in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyviews cost less than a single service call.

www.ingen-tech.com

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Contact:

Ingen Technologies, Inc.
Chris Wirth
909-790-7180
[e-mail]
www.INGEN-TECH.COM